Onychomycosis Treatment Market is Estimated to Expand at a Modest 8.60% CAGR through 2031

The Onychomycosis Treatment Market is set to grow from USD 4.91 billion in 2023 to USD 9.5 billion by 2031, driven by a CAGR of 8.60%. This growth is fueled by advances in treatment types like drugs and lasers, with a focus on disease indications, age groups, and gender demographics. The market spans diverse distribution channels and regions, presenting vast opportunities for expansion.
Global [https://www.skyquestt.com/report/onychomycosis-treatment-market] was valued at USD 4.91 billion in 2023 to USD 9.5 billion by 2031, growing at a CAGR of 8.60% during the forecast period (2024-2031). The prevalence of onychomycosis is increasing worldwide due to the expanding geriatric population base. Growing awareness regarding nail health is also expected to favor the demand for onychomycosis treatment over the coming years. The rising incidence of diabetes among the global population is also expected to bolster onychomycosis treatment market growth across the study period and beyond.

High investments in the research and development of novel treatments and advancements in medical technologies are also expected to create a new business scope for onychomycosis treatment companies going forward. Developing novel onychomycosis treatment products will pay off big time for all market players but targeting the proper management of disease through other products will also help them increase their revenue generation potential.

To Learn More About This Report, Request a Free Sample Copy - https://www.skyquestt.com/sample-request/onychomycosis-treatment-market

Launching New Products for Onychomycosis Treatment Helps Keep Market Players Competitive

The global onychomycosis treatment market is poised for steady growth over the coming years and this will help established companies extend their advantage. Gaining approvals for novel treatment products will be a crucial step for almost all companies operating in this market. Entering emerging markets and raising more awareness regarding onychomycosis will also be preferred strategies for onychomycosis treatment providers to improve their market share. Partnerships, acquisitions, and mergers are also estimated to be highly popular strategies opted by onychomycosis treatment companies to enhance their market presence on a global level.

Recently in June 2024, Renata Plc, a renowned pharmaceutical company based in Bangladesh announced that it had shipped its first consignment of onychomycosis treatment to the United Kingdom. Terbinafine 250 mg tablets were expected to be commercialized in the UK under a MHRA-approved facility.

In July 2021, Almirall S.A., a Spanish pharmaceutical company announced that it had acquired the exclusive rights to develop and commercialize efinaconazole's topical formulation in Europe from Kaken Pharmaceutical who discovered it in the first place. This expanded the availability of onychomycosis treatment for patients in Europe.

Lupin, a leading pharmaceutical organization based in India, announced the launch of a new generic topical onychomycosis treatment in the United States market in July 2021. Tavaborole Topical Solution was launched as a generic alternative onychomycosis treatment in the US after being approved by the Food and Drug Administration (FDA).

Recently in January 2024, the United States Food and Drug Administration (FDA) approved an Investigational New Drug (IND) application from Vanda Pharmaceuticals for a new onychomycosis treatment. VTR-297 is a topical antifungal developed for treating onychomycosis.

Get Customization on this Report for Specific Research Solutions: https://www.skyquestt.com/speak-with-analyst/onychomycosis-treatment-market

Onychomycosis Treatment Market Segmental Analysis:

Treatment Type

Drugs (Oral, Tropical)

Lasers

Photodynamic Therapy

Disease Indication

Distal Subungual Onychomycosis

White Superficial Onychomycosis

Proximal Subungual Onychomycosis

Candidal Onychomycosis

Total Dystrophic Onychomycosis

Age Group

0 to 18 Years

19 to 39 Years

40 to 64 Years

65 Years & Above

Gender

Male

Female

Distribution Channel

Institutional Sales (Hospitals, Dermatology Clinics)

Retail Sales (Retail Pharmacies, Drug Stores, Mail Order Pharmacies & Online Sales)

Take Action Now: Secure Your Onychomycosis Treatment Industry Today - https://www.skyquestt.com/buy-now/onychomycosis-treatment-market

Top Player's Company Profiles:

Teva Pharmaceutical Industries Ltd. (Israel)

Sanofi S.A. (France)

Medimetriks Pharmaceuticals, Inc. (US)

Galderma (Switzerland)

Johnson & Johnson (US)

Novartis AG (Switzerland)

Moberg Pharma AB (Sweden)

Cardinal Health, Inc. (US)

Pfizer Inc. (US)

Almirall, S.A. (Spain)

Bayer AG (Germany)

Viatris Inc. (US)

GlaxoSmithKline plc (UK)

Cipla Ltd. (India)

Dr. Reddy's Laboratories Ltd. (India)

Evofem Biosciences, Inc. (US)

Nabriva Therapeutics plc (Ireland)

Kaken Pharmaceutical Co., Ltd. (Japan)

Hikma Pharmaceuticals PLC (UK)

Dermavant Sciences, Inc. (US)

Sientra, Inc. (US)

Zynerba Pharmaceuticals, Inc. (US)

Increasing approvals of novel products for onychomycosis treatment will continue to keep this market opportune for all market players. New companies will have a hard time entering the market and succeeding owing to the high market share of established onychomycosis treatment providers. Collaboration will be highly crucial in determining the success of any onychomycosis treatment company in the long run.

Read Onychomycosis Treatment Industry Report Today - https://www.skyquestt.com/report/onychomycosis-treatment-market

Media Contact
Company Name: Skyquest Technology
Contact Person: Mr. Jagraj Singh
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=onychomycosis-treatment-market-is-estimated-to-expand-at-a-modest-860-cagr-through-2031]
Phone: +1 351-333-4748
Address:1 Apache Way, Westford,
Country: United States
Website: https://www.skyquestt.com/report/onychomycosis-treatment-market



This release was published on openPR.